

Please amend the application as follows:

IN THE CLAIMS¹

C1 24. (Three times amended) A method of producing a therapeutic polypeptide *in vitro*, comprising incubating a mammalian retinal pigment epithelial cell line in a biologically compatible medium such that the cell line produces the polypeptide, wherein the cell line is selected from the group consisting of hRPE-7, hRPE-116 and ARPE-19 and wherein the cells of the cell line comprise an expression vector comprising a polynucleotide coding for the polypeptide selected from the group consisting of BDNF, NT-4, CNTF, Axokine, IGF I, IGF II, TGF β -II, Midkine, IL-1 β , TNF, NGF, IL-2/3, ILF, IL-6, NTN, Neublastin, VEGF, GDNF, PDGF, LEDGF and PEDF.

C2 37. (Three times amended) The cell line IO/JG2/1, deposited under I-1695 on April 18, 1996 in the Collection Nationale de Cultures de Micro-organismes held by the Institut Pasteur, Paris France.

REMARKS

Claims 1, 10, 24, and 37 are currently pending in this application. Applicants have amended claims 24 and 37 to correct various informalities. These amendments do not constitute new matter.

Objections to the Claims

The Examiner has identified various informalities in claims 24 and 37. These claims have been amended as suggested by the Examiner, thereby obviating these objections.

¹ Applicants have attached Appendix A which illustrates the claim amendments in bracket and underline form.